Trial participation

We’ve been urging you to learn a few important points about your disease because HCM has various presentations and important metrics.

  • Are you obstructed or non-obstructed?
  • What is your Ejection Fraction – (EF)?
  • What is your NYHA functional class?
  • If you have a genetic mutation, if so, what is it?

Knowing the answers to these questions gives a healthcare provider a snapshot of your disease and also facilitates eligibility for clinical trials.  

Current trials:

  • The first is the Study of Mavacamten in Non-Obstructive Hypertrophic Cardiomyopathy (ODYSSEY-HCM) – For more information please complete this survey:
  • Other myosin inhibitor trials regarding the Efficacy and Safety of Aficamten For information about this and other trials please complete the survey:
  • MyPeak-1 is actively enrolling patients with nonobstructive HCM who have the MYBPC3 genetic mutation. For more information please complete this survey:
  • For our younger HCM community members with the MYBPC3 gene, a study: Natural History Study in Pediatric Patients With MYBPC3 Mutation-associated Cardiomyopathy (MyCLIMB).

If you are interested in any of these trial opportunities, please send me an email with your contact information – my email is or

If you haven’t gone through the HCMA Intake process within the last two years, please schedule an Intake Call on the website . 

This will give us the best understanding of your current health, HCM presentation, and potential eligibility in upcoming trials.

Leave a Comment